Glizorem (Gliclazide)

Glizorem (gliclazide) is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan.

• Used as monotherapy when diet and exercise alone do not achieve glycemic control.
• Combined with other oral antidiabetic agents such as metformin to improve blood glucose lowering.
• Prescribed for patients with stable renal function who require a sulfonylurea.
• Adjusted in elderly patients to reduce risk of hypoglycemia.
• May be considered when a long‑acting sulfonylurea is preferred.

The safety profile of Glizorem reflects the typical effects observed with sulfonylurea medications, ranging from mild, frequently reported events to rare but serious reactions.

Common

• Mild hypoglycemia, especially if meals are missed or delayed.
• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Transient visual disturbances such as blurred vision.
• Mild fatigue or weakness.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including skin rash, pruritus, or angio‑edema.
• Hematologic abnormalities such as leukopenia or thrombocytopenia.
• Hepatic dysfunction presenting as jaundice or elevated liver enzymes.
• Pancreatitis presenting with upper abdominal pain.
• Cardiovascular events such as arrhythmia.

When prescribing Glizorem, clinicians consider several precautions to minimize risks and ensure safe use in diverse patient populations.

• Assess renal and hepatic function before initiating therapy and periodically thereafter.
• Use lower starting doses in elderly patients or those with reduced kidney function.
• Monitor blood glucose closely to avoid hypoglycemia, especially when dietary patterns change.
• Counsel patients on recognizing signs of low blood sugar and the importance of regular meals.
• Avoid use during pregnancy or breastfeeding unless benefits clearly outweigh potential risks.
• Review concomitant medications that may potentiate hypoglycemia.

Glizorem may interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or insulin that can cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise gliclazide plasma levels.
• MAO‑B inhibitors, which have been reported to enhance sulfonylurea hypoglycemic action.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may displace gliclazide from plasma proteins, increasing free drug.

Use with caution

• Beta‑blockers, as they may mask hypoglycemia symptoms.
• Thiazide diuretics, which can affect blood glucose control.
• Corticosteroids, because they may increase glucose levels and require dose adjustments.
• Alcohol consumption, which can potentiate hypoglycemia and should be limited.